| Literature DB >> 34079268 |
Chikako Ichikawa1, Sho Tanaka2,3, Masahiro Takubo1,3, Masaru Kushimoto3, Jin Ikeda3, Katsuhiko Ogawa3,4, Ichiro Tsujino3,5, Yutaka Suzuki3,4, Masanori Abe2, Hisamitsu Ishihara1, Midori Fujishiro1,3.
Abstract
The standard six-month tuberculosis (TB) treatment comprises an intensive phase lasting two months, followed by a continuation phase lasting four months. Meanwhile, the nine-month regimen, which has a prolonged continuation phase, is indicated for patients with complicated diabetes mellitus (DM) because of their poor response to treatment. A 61-year-old Japanese man with poorly controlled DM for five years presented with bilateral scrotal swelling noticed two weeks ago. He had a history of pleuritis, pericarditis, and peritonitis two years ago. These symptoms led to the diagnosis of culture-negative extrapulmonary TB. He received the nine-month chemotherapy regimen (isoniazid, rifampin, pyrazinamide, and ethambutol for two months, followed by isoniazid and rifampin for seven months), and his symptoms significantly improved. The swollen scrotum was accompanied by mild tenderness and pus discharge from a fistula. Imaging study revealed bilaterally diffusely enlarged epididymis. However, the acid-fast bacilli smear and culture and polymerase chain reaction using urine and pus discharge tested negative. Bilateral epididymectomy was performed. Although the acid-fast bacilli smear was negative, the pathology demonstrated granuloma formation and acid-fast bacilli tissue culture confirmed multi-drug resistant Mycobacterium tuberculosis. The optimal treatment regimen and duration for extrapulmonary TB with unknown drug susceptibility are debatable. The nine-month regimen can be insufficient in some cases. Thus, detailed follow-up is essential, and TB relapse should be thoroughly monitored.Entities:
Keywords: chemotherapy; diabetes mellitus; epididymitis; tuberculosis
Year: 2021 PMID: 34079268 PMCID: PMC8164866 DOI: 10.2147/TCRM.S310463
Source DB: PubMed Journal: Ther Clin Risk Manag ISSN: 1176-6336 Impact factor: 2.423